Summit Extends Gains as Cancer Drug Outperforms BeiGene's Tevimbra
Zai Lab To Present Data From Phase 1 Trial Of DLL3-Targeted Antibody-Drug Conjugate ZL-1310 At 2025 ASCO Annual Meeting
Summit Therapeutics' Partner Akeso HARMONi-6/AK112-306 Phase 3 Trial Of Ivonescimab In Combination With Platinum-based Chemotherapy Compared With Tislelizumab Met Its Primary Endpoint Of Progression-Free Survival For Locally Advanced Or Metastatic...
Trending Industry Today: INNOCARE Leads Gains In Biotechnology Stocks
JP Morgan Maintains Overweight on BeiGene, Raises Price Target to $317
After the unsuccessful privatization of HENLIUS, FOSUN PHARMA took action to increase its Shareholding. Is it continuing to send Bullish signals? | Quick read of the announcement.
① After the privatization failure last year, FOSUN PHARMA continues to signal its bullish outlook on HENLIUS, and today increased its shareholding in HENLIUS; ② HENLIUS had impressive performance last year, and recently has been actively releasing positive news.
投机的阿妍 : The USA business has been sold, now is the time to buy at a discount.